Market Overview

D.A. Davidson Reiterates Buy, Lowers PT On Greif On Another Quarter, Another Miss

Share:

In a report published Friday, D.A. Davidson analyst Steven Chercover reiterated a Buy rating on Greif, Inc. (NYSE: GEF), but lowered the price target from $50.00 to $45.00.

In the report, D.A. Davidson noted, "Greif reported Q1-15 operating earnings of $0.30, as compared to earnings of $0.46 in Q1-14 and down from $0.86 in Q4-14 (GEF has restated historical numbers). The results fell short of our $0.37 estimate, with both the top line and bottom line missing due in part to currency and a higher than anticipated (and guided tax) rate. GAAP earnings of $0.52 were down a penny from Q1-14 and include a $24 million gain on timberland, which should properly be excluded. Management has reaffirmed its FY-15 earnings guidance of $2.25 to $2.35 – we suspect guidance had a margin of error baked in, or it will be tough to attain."

Greif closed on Thursday at $37.78.

Latest Ratings for GEF

DateFirmActionFromTo
Dec 2018MaintainsOutperformOutperform
Dec 2018DowngradesOutperformUnderperform
Dec 2018DowngradesOutperformMarket Perform

View More Analyst Ratings for GEF
View the Latest Analyst Ratings

Posted-In: D.A. Davidson Steven ChercoverAnalyst Color Price Target Analyst Ratings

 

Related Articles (GEF)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
LOWRBC CapitalMaintains129.0
MARRBC CapitalMaintains148.0
CRLSunTrust Robinson HumphreyMaintains162.0
CFRSunTrust Robinson HumphreyMaintains105.0
ZYNEJefferiesAssumes11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Nomura Downgrades Pharmacyclics To Neutral

What This Market Expert Thinks Of Greece And The ECB